ShoreHaven Wealth Partners’s AstraZeneca AZN Stock Holding History

ShoreHaven Wealth Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-16	Closed	-$2K	–	76
2021 Q1	$2K	Buy	+16	New	+$1.61K	﹤0.01%	249

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

ShoreHaven Wealth Partners's AZN Position: Q2 2021 in Review

ShoreHaven Wealth Partners sold out of AstraZeneca (AZN) in Q2 2021, closing a stake of 16 shares — an estimated $2K sold.

ShoreHaven Wealth Partners first reported a position in AZN in Q1 2021 and held it in 1 quarter. The position peaked at $2K in Q1 2021. 771 funds tracked by Wall St. Rank hold AZN as of Q2 2021.

ShoreHaven Wealth Partners reported no remaining AstraZeneca position as of Q2 2021 after selling out during the quarter.
ShoreHaven Wealth Partners sold 16 AstraZeneca shares in Q2 2021, an estimated $2K.
ShoreHaven Wealth Partners first reported a position in AstraZeneca in Q1 2021 and held it in 1 quarter.
ShoreHaven Wealth Partners's AstraZeneca position peaked at $2K in Q1 2021.
771 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2021.

Based on ShoreHaven Wealth Partners's 13F filing for Q2 2021, filed 16 Aug 2021.